Cargando…

Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time

BACKGROUND: The symptoms of coronavirus disease 2019 (COVID-19) appear to be heterogenous, and the typical course of these symptoms is unknown. Our objectives were to characterize the common trajectories of COVID-19 symptoms and to assess how symptom course predicts other symptom changes as well as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodebaugh, Thomas L, Frumkin, Madelyn R, Reiersen, Angela M, Lenze, Eric J, Avidan, Michael S, Miller, J Philip, Piccirillo, Jay F, Zorumski, Charles F, Mattar, Caline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989225/ https://www.ncbi.nlm.nih.gov/pubmed/33796601 http://dx.doi.org/10.1093/ofid/ofab090

Ejemplares similares

The long road from person-specific models to personalized mental health treatment
por: Rodebaugh, Thomas L., et al.
Publicado: (2020)

The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
por: Reiersen, Angela M, et al.
Publicado: (2023)

SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids
por: Izumi, Yukitoshi, et al.
Publicado: (2023)

The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge
por: Xia, Lu, et al.
Publicado: (2020)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19
por: Moser, Carlee, et al.
Publicado: (2022)

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort
por: Laake, Ida, et al.
Publicado: (2022)

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Plasmodium–Helminth Coinfection and Its Sources of Heterogeneity Across East Africa
por: Brooker, Simon J., et al.
Publicado: (2012)

Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders
por: Lenze, Eric J., et al.
Publicado: (2021)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD
por: Johnson, Kate M, et al.
Publicado: (2018)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
por: Ison, Michael G, et al.
Publicado: (2023)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Influence of Mild White Matter Lesions on Voxel-based Morphometry
por: Goto, Masami, et al.
Publicado: (2020)

When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials
por: Mofsen, Aaron M, et al.
Publicado: (2019)

Association Between Foot Surgery Type and Subsequent Healing in Veterans With Moderate-to-Severe Diabetic Foot Infections
por: Kim, Justin J, et al.
Publicado: (2021)

Trends in Bacteremia Over 2 Decades in the Top End of the Northern Territory of Australia
por: Douglas, Nicholas M, et al.
Publicado: (2020)

Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease
por: Lin, Chung-Hsien, et al.
Publicado: (2019)

Challenges Across the HIV Care Continuum for Patients With HIV/TB Co-infection in Atlanta, GA
por: Schechter, Marcos C, et al.
Publicado: (2018)

Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing for Obstetric Inpatient Units Across the United States
por: Gilner, Jennifer, et al.
Publicado: (2021)

Heterogeneity Between States in the Health and Economic Impact of Measles Immunization in the United States
por: Paternina-Caicedo, Angel, et al.
Publicado: (2018)

Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials
por: Portsmouth, Simon, et al.
Publicado: (2021)

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
por: Kumar, Princy N, et al.
Publicado: (2021)

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

2192 The association of preoperative functional capacity and outcomes for head and neck cancer patients undergoing definitive surgical treatment
por: Sindhar, Sampat, et al.
Publicado: (2018)

Room for Improvement: The HIV–Diabetes Care Continuum Over 15 Years in the Women’s Interagency HIV Study
por: Colasanti, Jonathan, et al.
Publicado: (2018)

Comparative COVID-19 Vaccine Effectiveness Over Time in Veterans
por: Mayr, Florian B, et al.
Publicado: (2022)

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
por: Sasson, Jennifer, et al.
Publicado: (2022)

Development of a Centralized Antimicrobial Stewardship Program Across a Diverse Health System and Early Antimicrobial Usage Trends
por: Khadem, Tina M, et al.
Publicado: (2022)

Genomic Heterogeneity of Cryptosporidium parvum Isolates From Children in Bangladesh: Implications for Parasite Biology and Human Infection
por: Carey, Maureen, et al.
Publicado: (2023)

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
por: Fritz, Bradley A., et al.
Publicado: (2022)

Novel Human Parechovirus 3 Diversity, Recombination, and Clinical Impact Across 7 Years: An Australian Story
por: Bialasiewicz, Seweryn, et al.
Publicado: (2022)

Mortality Over Long-term Follow-up for People With HIV Receiving Longitudinal Care and Antiretroviral Therapy in Rural Haiti
por: Richterman, Aaron, et al.
Publicado: (2020)

Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
por: Ananworanich, Jintanat, et al.
Publicado: (2021)

Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations
por: Lessa, Fernanda C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rvbtnlr2jdqrcco7k0fchbtggq